Raj Reddy is a biotechnology pioneer and the President and CEO of Canary Cure, a leading gene and RNA therapy company developing innovative treatments for metabolic, obesity and rare genetic diseases. With over 10 years of experience scaling biotech ventures and specializing in the endocannabinoid system's role in metabolic health, Raj brings deep expertise in pharmacology and medicinal chemistry to the company's groundbreaking work. As the inventor on over 20 patents in genetics and RNA therapy, Raj leads Canary's development of first-in-class siRNA therapeutics that transform white adipose tissue into energy-burning powerhouses. His flagship innovation, CCT-217, demonstrates unprecedented outcomes in pre-clinical models—achieving 26% weight loss while increasing lean muscle mass by 25%, a stark contrast to current therapies that cause significant muscle deterioration. Raj's strategic vision combines cutting-edge RNA technology with AI-enhanced personalized approaches to revolutionize treatment paradigms. His previous leadership over a $500 million portfolio has honed his expertise in strategic management and market access. Driven by the transformative potential of genetic medicine, Raj is committed to unlocking new frontiers in precision medicine that enable earlier detection and more effective disease treatment through targeted genetic mechanisms.